migaldendranib oral (D-4517.2 oral) / Ashvattha Therap - LARVOL DELTA

Ashvattha to Present at Upcoming Angiogenesis, Exudation, and Degeneration 2025 and BIO CEO Conferences (GlobeNewswire) - "Ashvattha Therapeutics...today announced upcoming presentations at Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025 and the BIO CEO & Investor Conference being held on February 10-11, 2025 at the New York Marriott Marquis in New York City. Dr. Michael Singer will present interim Phase 2 results for migaldendranib (MGB), Ashvattha's investigational subcutaneous treatment for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME)."

P2 data • Age-related Macular Degeneration • Diabetic Macular Edema